Drug reference

Atovaquone with proguanil hydrochloride

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 673

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

MALARONE ® 250MG/100MG Prophylaxis of falciparum malaria, particularly where resistance to other antimalarial drugs suspected ▶BY MOUTH ▶Adult (body-weight 40 kg and above): 1 tablet once daily, to be started 1–2 days before entering endemic area and continued for 1 week after leaving Treatment of acute uncomplicated falciparum malaria | Treatment of non-falciparum malaria ▶BY MOUTH ▶Adult: 4 tablets once daily for 3 days DOSE EQUIVALENCE AND CONVERSION ▶Each tablet of Malarone ® contains 250 mg of atovaquone and 100 mg of proguanil hydrochloride. l UNLICENSED USE Not licensed for treatment of non- falciparum malaria.

PDF page 673

Cautions

Diarrhoea or vomiting (reduced absorption of atovaquone). efﬁcacy not evaluated in cerebral or Infection complicated malaria (including hyperparasitaemia, pulmonary oedema or renal failure)

PDF page 673

National Funding Access Decisions

NHS restrictions Drugs for malaria prophylaxis are not prescribable in NHS primary care; health authorities may investigate circumstances under which antimalarials are prescribed.

PDF page 673

Safety

Interactions

→Appendix 1: antimalarials

PDF page 673

Side Effects

▶Common or very common Abdominal pain. appetite decreased. cough. depression. diarrhoea. dizziness. fever . headache. nausea. skin reactions. sleep disorders. vomiting ▶Uncommon Alopecia. anxiety. blood disorder. hyponatraemia. oral disorders. palpitations ▶Frequency not known Hallucination. hepatic disorders. photosensitivity reaction. seizure. Stevens-Johnson syndrome. tachycardia. vasculitis

PDF page 673

Pregnancy

Manufacturer advises use only if potential beneﬁt outweighs risk. See also Pregnancy in Malaria, prophylaxis p. 643.

PDF page 673

Breast Feeding

Use only if no suitable alternative available.

PDF page 673

Renal Impairment

Avoid for malaria prophylaxis (and if possible for malaria treatment) if eGFR less than 30 mL/minute/1.73m2.

PDF page 673

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 21 ▶Malarone (GlaxoSmithKline UK Ltd) Proguanil hydrochloride 100 mg, Atovaquone 250 mg Malarone 250mg/100mg tablets | 12 tablet P £25.21 DT = £31.69

PDF page 673

Clinical care

Patient And Carer Advice

Warn travellers about importance of avoiding mosquito bites, importance of taking prophylaxis regularly, and importance of immediate visit to doctor if ill within 1 year and especially within 3 months of return.

PDF page 673

Dose text by age group

Adult (body-weight 40 kg and above)

1 tablet once daily,

First-line fragment. Read the complete Indications and Dose section above.

PDF page 673

Adult

4 tablets once daily for 3 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 673

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Atovaquone with proguanil hydrochloride

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 673

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 673

Cautions

Diarrhoea or vomiting (reduced absorption of atovaquone). efﬁcacy not evaluated in cerebral or Infection complicated malaria (including hyperparasitaemia, pulmonary oedema or renal failure)

PDF page 673

National Funding Access Decisions

NHS restrictions Drugs for malaria prophylaxis are not prescribable in NHS primary care; health authorities may investigate circumstances under which antimalarials are prescribed.

PDF page 673

Safety

Interactions

→Appendix 1: antimalarials

PDF page 673

Side Effects

PDF page 673

Pregnancy

Manufacturer advises use only if potential beneﬁt outweighs risk. See also Pregnancy in Malaria, prophylaxis p. 643.

PDF page 673

Breast Feeding

Use only if no suitable alternative available.

PDF page 673

Renal Impairment

Avoid for malaria prophylaxis (and if possible for malaria treatment) if eGFR less than 30 mL/minute/1.73m2.

PDF page 673

Dose and formulations

Medicinal Forms

PDF page 673

Clinical care

Patient And Carer Advice

PDF page 673

Dose text by age group

Adult (body-weight 40 kg and above)

1 tablet once daily,

First-line fragment. Read the complete Indications and Dose section above.

PDF page 673

Adult

4 tablets once daily for 3 days

First-line fragment. Read the complete Indications and Dose section above.

PDF page 673

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.